Nutriband Advances AVERSA™ Fentanyl Patch Toward FDA Submission with Scaled Manufacturing
Nutriband Inc. has scaled manufacturing for its abuse-deterrent fentanyl patch AVERSA™ through collaboration with Kindeva, positioning the company for FDA submission and potential global commercialization with established patent protection across multiple regions.
Nutriband Inc. (NASDAQ: NTRB) has achieved significant manufacturing scale-up for its lead product AVERSA™ Fentanyl, moving closer to FDA submission through its collaboration with manufacturing partner Kindeva. The company's proprietary technology incorporates aversive agents into transdermal fentanyl patches designed to prevent misuse, abuse, diversion, and accidental exposure to the potent opioid medication.
The manufacturing advancement represents a critical milestone in Nutriband's development pathway, potentially unlocking substantial revenue opportunities upon regulatory approval. The company has established a comprehensive global intellectual property protection strategy, securing patents across the United States, Europe, Asia, and Australia for its AVERSA™ abuse-deterrent technology platform.
This technology platform holds potential application beyond fentanyl, as it can be incorporated into any transdermal patch containing drugs with abuse potential. The company maintains a focused approach toward finalizing its development program in preparation for regulatory submissions. Additional information about Nutriband's development programs is available at https://www.Nutriband.com.
The advancement of abuse-deterrent opioid formulations addresses a critical public health need amid ongoing concerns about prescription drug misuse. Regulatory approval of such technologies could provide healthcare providers with additional tools for managing pain treatment while mitigating risks associated with opioid medications. Investors and stakeholders can monitor company developments through its newsroom at https://ibn.fm/NTRB.